FDA approves its Cequa for treatment of dry corneal conjunctivitis

dry eye disease is one of the most common eye diseases, with an estimated 16 million U.Sadults diagnosed with dry eye diseaseDry eye disease is a multi-factor disease associated with the surface of the eye and the secretion of tears, often the amount or quality of tear secretion can not achieve the correct lubrication of the eyerecently, Sun Pharma announced thatFDA(approved 0.09% of its Cequa (cyclosporine eye fluid) to increase the production of tear spacta and treat dry corneal conjunctivitis (dry eye disease)CequaSun Pharma's Cequa is a cyclosporine A (CsA) nano-binding preparationThe preparation is a gel-like aggregate formed at a specific concentration by two-parent (hydrophobic and hydrophilic) moleculesCequa is the highest concentration approved by the FDA to date and the only CsAPharmaceutical(a patentedofIts binding formula allows CsA molecules to overcome solubility limitations, penetrate the eye's water layer and prevent active pro-fat molecules from being released before penetrationNanoscales, on the other hand, helptheof the drug (into the cornea and conjunctiva cells), which can deliver high concentrations of CsA and improve inflammation on the surface of the eye 　　Cequa's approval is based on the positive results of its phase 3 trial The results showed that after 12 weeks of treatment, Cequa achieved a statistical lysion improvement in the Schirmer score, a measure of the yield of tears, compared to the empty drug vector (vehicle) The new drug (and also resulted in statistically significant improvements) at several secondary endpoints, including eye staining assessments